AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq ...

Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...

President Donald Trump assured that the United States will continue to supply liquefied natural gas (LNG) to Europe, despite concerns that the growing export industry could increase domestic gas ...

The Trump administration urged U.S. Agency for International Development (USAID) workers to join the effort to transform how ...

Sage (SAGE) is reportedly suing Biogen (BIIB) over enforcement of a standstill agreement in the wake of an unsolicited takeover bid valued at around $469M. Read more here.

Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, specializes in discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases ...

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the smaller neuroscience company for about $469 million. The lawsuit remains ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target of $138.00. The company’s shares closed yesterday ...

Moreover, Biogen’s valuation appears to be fairly priced at current levels, as indicated by a Discounted Cash Flow analysis projecting revenues through 2033. While the company has potential ...

Are you a print subscriber? Activate your account. By Ewan Larkin - 2 hours 3 min ago By Ad Age and Creativity Staff - 3 hours 56 min ago By Ad Age Staff - 4 hours 7 min ago By E.J. Schultz - 5 ...